Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles

被引:5
作者
Ruwona, Tinashe B. [1 ]
Xu, Haiyue [1 ]
Li, Junwei [2 ]
Diaz-Arevalo, Diana [2 ]
Kumar, Amit [1 ]
Zeng, Mingtao [2 ]
Cui, Zhengrong [1 ]
机构
[1] Univ Texas Austin, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA
[2] Texas Tech Univ, Hlth Sci Ctr El Paso, Ctr Emphasis Infect Dis, Dept Biomed Sci, El Paso, TX USA
关键词
antibody responses; botulinum neurotoxin; mouse survival; PLGA nanoparticles; EQUINE ENCEPHALITIS-VIRUS; CHAIN FRAGMENT-C; CLOSTRIDIUM-BOTULINUM; PICHIA-PASTORIS; BINDING DOMAIN; DNA VACCINES; SCALE-UP; VACCINATION; PURIFICATION; IMMUNOGENICITY;
D O I
10.1080/21645515.2015.1122147
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Botulinum neurotoxin (BoNT) is a lethal neurotoxin, for which there is currently not an approved vaccine. Recent efforts in developing vaccine candidates against botulism have been directed at the heavy chain fragment of BoNT, because antibodies against this region have been shown to prevent BoNT from binding to its receptor and thus to nerve cell surface, offering protection against BoNT intoxication. In the present study, it was shown that immunization with plasmid DNA that encodes the 50 KDa C-terminal fragment of the heavy chain of BoNT serotype C (i.e., BoNT/C-Hc50) and is carried by cationic poly (lactic-co-glycolic) acid (PLGA) nanoparticles induces stronger BoNT/C-specific antibody responses, as compared to immunization with the plasmid alone. Importantly, the antibodies have BoNT/C-neutralizing activity, protecting the immunized mice from a lethal dose of BoNT/C challenge. A plasmid DNA vaccine encoding the Hc50 fragments of BoNT serotypes that cause human botulism may represent a viable vaccine candidate for protecting against botulinum neurotoxin intoxication.
引用
收藏
页码:1188 / 1192
页数:5
相关论文
共 33 条
[1]  
Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1454
[2]   Mode of Action of Botulinum Neurotoxins: Current Vaccination Strategies and Molecular Immune Recognition [J].
Aoki, K. Roger ;
Smith, Leonard A. ;
Atassi, M. Zouhair .
CRITICAL REVIEWS IN IMMUNOLOGY, 2010, 30 (02) :167-187
[3]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[4]   Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions [J].
Atassi, M. Z. .
TOXICON, 2015, 107 :50-58
[5]  
Atassi MZ, 1999, CRIT REV IMMUNOL, V19, P219
[6]   A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins [J].
Barash, Jason R. ;
Arnon, Stephen S. .
JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (02) :183-191
[7]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[8]   DNA vaccination protects against botulinum neurotoxin type F [J].
Bennett, AM ;
Perkins, SD ;
Holley, JL .
VACCINE, 2003, 21 (23) :3110-3117
[9]   Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate [J].
Byrne, MP ;
Smith, TJ ;
Montgomery, VA ;
Smith, LA .
INFECTION AND IMMUNITY, 1998, 66 (10) :4817-4822
[10]   Development of vaccines for prevention of botulism [J].
Byrne, MP ;
Smith, LA .
BIOCHIMIE, 2000, 82 (9-10) :955-966